Differences in study design may explain the large variety in different signalling pathways proposed for galectin-1 in insulin resistance and highlight the need for additional mechanistic studies elucidating which of these interactions are of highest clinical relevance. This evidence concerns the gene LGALS1 and Insulin resistance.